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Abstract
Objectives. This analysis set out to estimate the risk of opportunistic infection (OI) among patients with
RA by biologic class.
Methods. The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis is a prospective
observational cohort study established to evaluate safety of biologic therapies. The population included adults
commencing biologic therapy for RA. The primary outcome was any serious OI excluding tuberculosis (TB).
Event rates were compared across biologic classes using Cox proportional hazards with adjustment for
potential confounders identified a priori. Analysis of the incidence of TB was performed separately.
Results. In total, 19 282 patients with 106 347 years of follow-up were studied; 142 non-TB OI were
identified at a rate of 134 cases/100 000 patient years (pyrs). The overall incidence of OI was not signifi-
cantly different between the different drug classes; however, the rate of Pneumocystis infection was
significantly higher with rituximab than with anti-TNF therapy (adjusted hazard ratio = 3.2, 95% CI: 1.4,
7.5). The rate of TB fell dramatically over the study period (783 cases/100 000 pyrs in 2002 to 38 cases/
100 000 pyrs in 2015). The incidence of TB was significantly lower among rituximab users than anti-TNF
users, with 12 cases/100 000 pyrs compared with 65 cases/100 000 pyrs.
Conclusions. The overall rate of OI was not significantly different between drug classes; however, a
subtle difference in the pattern of OI was seen between the cohorts. Patient factors such as age,
gender and comorbidity were the most important predictors of OI.
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Rheumatology key messages
. Opportunistic infections affect 0.1% of RA patients receiving biologic therapy each year.
. Tuberculosis rates have fallen among biologic users with RA since pre-screening guidelines were introduced.
. The incidence of tuberculosis is significantly lower with rituximab than with anti-TNF in RA.
Introduction
Modern treatment of RA has been revolutionized by the
advent of biologic therapies. For most patients, these
drugs represent a safe and efficacious treatment strategy;
however, serious infections associated with biologic thera-
pies are a significant concern for patients and clinicians.
Registry data from the UK and Sweden have shown an
increased risk of serious infection in new anti-TNF starters,
especially in the first 612 months of therapy [1, 2].
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Many of these infections will be due to the same organisms
seen commonly in the general population but a small pro-
portion will be due to opportunistic organisms that would
not typically cause infections in an immunocompetent
individual.
Much of the early literature on opportunistic infections
(OI) comes from patients with HIV or cancer. In this set-
ting, OI are often defined as infections that are more fre-
quent or more severe because of immunosuppression in
HIV-infected persons [3]. However, it could be argued that
according to this definition all infections are OI. Winthrop
et al. [4] published evidence-driven consensus recom-
mendations for the reporting of OI in rheumatology clinical
trials and surveillance studies, identifying 24 infections as
definite OI and 11 infections as probable OI.
Clinical trials are not powered to detect a change in the
incidence of rare events such as OI. The original British
Society for Rheumatology Biologics Register for
Rheumatoid Arthritis (BSRBR-RA) TNF inhibitor (TNFi) re-
cruitment target was chosen to provide adequate statistical
power to ascertain a doubling in the incidence of lymphoma
between the cohorts. This was based on lymphoma having
an incidence of approximately 1 in 1000. As such, the
BSRBR-RA is powered to detect differences in the rates
of other rare events following TNFi with a similar incidence.
The primary outcome of this analysis was to estimate
the incidence of serious (defined as requiring hospitaliza-
tion, intravenous antimicrobial therapy or resulting in
death) OI among individuals with RA treated with biologic
therapy.
Methods
We used data from the BSRBR-RA, a prospective obser-
vational cohort study established in 2001, to evaluate the
safety of biologic therapies. Initially, there were just three
cohorts of patients (etanercept, infliximab and a compara-
tor group of patients treated with existing DMARDs).
Further cohorts studying adalimumab, rituximab, certoli-
zumab-pegol and tocilizumab have since been recruited.
The BSRBR-RA methodology has been described previ-
ously [5].
The population studied were adults commencing bio-
logic therapy for RA. Subjects were considered at risk
from treatment start until the date of OI, five half-lives
after drug stop, death or last follow-up before June
2016, whichever came first. For the rituximab cohort pa-
tients were considered at risk until 270 days after the last
infusion. If two infusions were separated by >270 days,
the subject was considered to have been continuously
exposed, reflecting the varying dosing frequency of
rituximab.
We chose to analyse all anti-TNF drugs together, as
given that they share a common mode of action we
would expect to see a similar pattern of OI across the
drugs and to increase the power of the study. Sensitivity
analyses were performed to see if there was any in-class
variation in the rates of OI.
The primary outcome was any serious OI as defined by
Winthrop et al. [4], excluding tuberculosis (TB). Both definite
and probable OI were included in analysis, although a sen-
sitivity analysis was performed including only definite OI.
We made an a priori decision to exclude TB from the
main analysis, for two reasons. First, it has previously
been reported within the BSRBR-RA [6]. Secondly, guide-
lines and pre-screening for TB have changed over time
with increasing availability of IFNg release assays, thus
comparison of newer cohorts of biologic-treated patients
with older cohorts would lead to biased results. A separ-
ate analysis looking only at TB was performed.
All OI were validated independently by two clinicians
(A.I.R. and E.P.) who were blinded to the treatment expos-
ure. Differences in coding were resolved by discussion or, if
consensus could not be reached, by a third clinician (J.B.G.).
Event rates were compared across biologic classes
using Cox proportional hazards with adjustment for age,
gender, disease severity and duration, smoking, seroposi-
tivity and polypharmacy (as a surrogate for comorbidity).
Missing baseline data were imputed using the Imputation
by Chained Equations, ICE package in Stata 14
(StataCorp, College Station, TX, USA).
The BSRBR-RA was approved by the North-West
Multicentre Research Ethics Committee (MREC 00/8/
053, IRAS: 64202) and all patients gave written informed
consent; this analysis did not require additional ethical
approval.
Results
In total, 19 282 patients with 106 347 years of follow-up
were studied. There were 85 331 years of patient follow-
up in the anti-TNF cohort comprising of 36 663 years on
etanercept, 17 670 years on infliximab, 28 751 years on
adalimumab and 2247 years on certolizumab-pegol.
Some 5072 patients were exposed to rituximab with
17 154 years of follow-up and 2171 patients were
exposed to tocilizumab with 3861 years of follow-up. No
patients receiving a biosimilar product were included in
this analysis. Baseline characteristics are presented in
supplementary Table S1, available at Rheumatology
online.
One hundred and sixty-one events were identified, of
which 142 were validated as OI by the two blinded asses-
sors. The remaining 19 events did not meet criteria for
inclusion. The overall incidence of non-TB OI was 134
cases/100 000 patient years (pyrs). The most common
OI seen with anti-TNF therapy were herpes zoster (HZ)
infection (54/114 cases), Pneumocystis jiroveci pneumo-
nia (PJP, 15/114 cases) and legionella (11/114 cases).
With rituximab therapy, PJP was the most frequently
observed OI (9/25 cases) followed by HZ (7/25 cases).
The follow-up was shorter in the tocilizumab cohort with
just three OI recorded, all with different organisms.
There was no difference in overall rates of OI across
biologics in the unadjusted or fully adjusted model. Male
gender, increasing age, DAS28, HAQ, steroid usage and
polypharmacy were all predictors of OI in a univariate
model. Age, gender and polypharmacy remained signifi-
cant predictors in the multivariable model.
998 https://academic.oup.com/rheumatology










 Portugal user on 25 O
ctober 2019
Pattern of non-TB OI by drug
HZ was the most common OI seen in the register, with an
incidence of 59 cases/100 000 pyrs. There was no differ-
ence in the rate of serious HZ by drug class.
PJP infections were rare, with 23 cases/100 000 pyrs
(95% CI: 16, 35) though a higher rate was observed in the
rituximab cohort at 52 cases/100 000 pyrs (95% CI: 27,
100). The increased rate observed with rituximab com-
pared with anti-TNF was statistically significant in both
unadjusted (HR = 3.7, 95% CI: 1.6, 8.6) and adjusted
models (adjusted HR = 3.2, 95% CI: 1.4, 7.5).
There was no statistically significant difference in the
rates of Aspergillus infection between the drugs classes.
The remaining OI were too rare to allow any comparative
analysis between drug classes. No cases of progressive
multifocal leukoencephalopathy (PML) were recorded with
any of the drugs. The breakdown of each individual type of
OI is shown in supplementary Table S2, available at
Rheumatology online.
Tuberculosis infections
Fig. 1A shows the incidence of TB across all biologic
users in the BSRBR-RA by calendar year. The rate has
fallen from 783 cases/100 000 pyrs in 2002 to 38 cases/
100 000 pyrs in 2015, the latest year that complete data
were available for. Data from Public Health England were
extracted to allow comparison of the rate from the
BSRBR-RA with that seen in the general population in
England, and the results are shown in Fig. 1 [7].
The incidence of TB was significantly lower among
rituximab users than anti-TNF users, with 12 cases re-
corded per 100 000 pyrs compared with 65 cases/
100 000 pyrs (see Table 1). The difference remained stat-
istically significant in a sensitivity analysis looking at indi-
viduals who started biologic therapy after the year 2005.
The rate of TB by each individual anti-TNF drug is
shown in supplementary Table S3, available at
Rheumatology online. Etanercept had the lowest inci-
dence of TB of all the anti-TNF drugs but the rate was
still significantly higher than the rate with rituximab with
an adjusted HR = 4.63 (95% CI: 1.06, 20.2).
Discussion
This study is reassuring, showing that the overall inci-
dence of OI is low at just over 1 case in 1000 pyrs. This
is similar to results from the French Research Axed on
Tolerance of Biotherapies registry, which found that the
incidence of OI was 152 cases/100 000 years among anti-
TNF users [8]. There appeared to be no difference in the
overall rate of non-TB OI between the drugs, although
TABLE 1 Incidence of OI and TB by drug class
All biologics Anti-TNF Rituximab Tocilizumab
Opportunistic infections excluding TB
Survival time follow-up, years 106 347 85 331 17 154 3861
Number of OI 142 114 25 3
Unadjusted OI incidence rate per 100 000 pyrs (95% CI) 134 (113, 157) 134 (111, 161) 146 (98, 217) 78 (25, 241)
Unadjusted hazard ratio (95% CI) N/A Ref. 1.18 (0.76, 1.83) 0.56 (0.18, 1.76)
Adjusted hazard ratio (95% CI) N/A Ref. 0.96 (0.62, 1.50) 0.52 (0.17, 1.65)
TB infections
Number of TB cases 59 56 2 1
Incidence of TB per 100 000 pyrs (95% CI) 55 (43, 71) 65 (50, 85) 12 (3, 46) 26 (4, 183)
Adjusted HR for TB (95% CI) N/A Ref. 0.16 (0.04, 0.67) 0.35 (0.05, 2.55)
OI: opportunistic infections, TB: tuberculosis, HR: hazard ratio, pyrs: patient years.
FIG. 1 Incidence of TB by calendar year in the BSRBR-RA
compared with the general population
A
B
(A) Falling rate of TB by calendar year among all biologic
users within the BSRBR-RA. (B) Rate of TB in the general
population over the same time period—data provided by
Public Health England. TB: tuberculosis; BSRBR-RA:
British Society for Rheumatology Biologics Register for
RA.
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given the small size of the tocilizumab cohort it is difficult
to draw firm conclusions.
Subtle differences were seen in the pattern of non-TB
OI seen between drug classes. Most striking was the
higher incidence of PJP observed with rituximab. Animal
models have shown that B cells play a vital role in gener-
ation of CD4+ memory T cells in response to PJP infection
in the lungs [9]. The link between PJP and rituximab has
been described before, although the majority of docu-
mented cases come from the lymphoma treatment popu-
lation [10]. Corticosteroid exposure is a strong predictor of
developing PJP. In our cohort, 64% of PJP cases were on
oral steroids at the time of infection. A meta-analysis of
rituximab-treated lymphoma patients demonstrated that
PJP prophylaxis is highly effective at preventing subse-
quent infection [11]. It is important to remember that
PJP infection is rare, and while these data would not sup-
port PJP prophylaxis for all rituximab users it may be ap-
propriate in certain high-risk individuals.
No cases of PML were recorded despite over 100 000
pyrs of follow-up. This supports previous literature that PML
is extremely rare among biologic users with RA [12].
The incidence of TB in biologic-treated patients has
fallen dramatically since the inception of the BSRBR-RA.
This is not reflected in the general population, where the
rate of TB has remained stable over the same period. The
falling incidence observed in the BSRBR-RA is likely to
reflect improved screening and treatment of latent TB fol-
lowing the introduction of British Thoracic Society
Guidelines in 2005 [13]. Even in recent years the rate of
TB appears higher in the BSRBR-RA than that observed in
the general population, although the figures are obtained
using different methodology so it is difficult to draw strong
conclusions about relative risk. The link between TNFi and
TB has previously been established [6]. Keane et al. [14]
showed that patients with TB infection on infliximab failed
to form granulomas and had reduced macrophage apop-
tosis, hinting at a potential mechanism for why a higher
rate of TB is seen with anti-TNF when compared with
other biologics with different modes of action.
Previous studies using registries have mostly compared
the risk of starting a biologic with the risk of continuing
current DMARDs in patients with severe disease. This is
an increasingly irrelevant comparison, as most clinicians
faced with a patient who has not responded to DMARDs
will opt to start a biologic. When choosing a biologic,
safety is an important consideration, particularly in high-
risk groups. It is therefore vital to have directly compara-
tive studies of safety between biologic drugs.
The main strengths of this study are the use of real
world data from a large sample of biologic-treated pa-
tients with a long follow-up. It was interesting to note
that 58% of OI and 55% of TB occurred among individuals
who had been on a biologic for >1 year. These cases
might not have been detected in many clinical trials that
have shorter follow-up periods.
The main limitations of this study are those that will affect
any observational study. As the patients are not
randomized to each treatment arm there will be an element
of bias introduced. Most rituximab (93%) and tocilizumab
(89%) users in our cohort had already been exposed to
another biologic, including TNFi, and it is unclear what
impact sequential biologic exposure has on infection risk.
Conversely, patients who experienced an OI on a TNFi may
not have progressed on to sequential biologic therapy, thus
identifying a so-called healthier user cohort, at least in
terms of infection risk. There is likely to be channelling
bias, with rheumatologists more likely to use a drug that
they perceive to be safe in individuals who are at risk of
infection. Whilst we have tried to adjust for patient factors
in the model, there will always be some unmeasured con-
founders that we cannot adjust for.
Conclusions
OI are rare among individuals with RA treated with bio-
logics. In this analysis, drug choice was not a significant
predictor of the overall rates of OI, although subtle differ-
ences in the type of OI observed were seen between drug
classes. The strongest predictors of OI were unmodifiable
patient factors such as age, gender and comorbidity.
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Supplementary data are available at Rheumatology online.
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